姓名 王润玲
职称
教授
所在部门
药学院
研究方向
创新药物研究


办公室
药学院A楼302
办公电话

电子邮箱
wangrunling@tmu.edu.cn

教育背景

1978年8月—1982年7月北京大学医学部，本科学历，学士学位。
2003年8月—2006年7月天津大学，研究生学历，博士学位。

工作经历

2015.5-至今 天津医科大学药学院，教授
1999.10-2015.4 天津医科大学药学院，教授，副院长
1994.10-1999.9 天津医科大学药学院，副教授
1984.10-1994.9 天津医科大学药学院，讲师
1982.7-1984.9 天津医科大学药学院，助教

研究成果（本人具有代表性的论著、论文及主持的科研项目）

论著及编著

药物化学（主编）清华大学出版社，第一版，2013.7
药物化学（主编）医药科技出版社，第三版，2012.5，
药学专业化学实验Ⅱ（主编），人民卫生出版社，2008.7
药物化学（参编），人民卫生出版社，第七版，2011.8 7
药物化学（参编），中国医药科技出版社，第二版，2011.2
临床药物化学（编委），人民卫生出版社，2007.8
现代药物设计学（编委），中国医药科技出版社，2006
药物化学，清华大学出版社，2018.5，第二版，主编
药物化学，人民卫生出版社，2016.2，第八版，参编

论文

1. Jun Zhang, Xin Liu, Shu-Qing Wang, Gui-You Liu, Wei-RenXu, Xian-Chao Cheng*, Run-Ling Wang*. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan [J]. Journal of Biomolecular Structure and Dynamics, 2017, 35 (12): 2665–2680
2. Yue-Qin Zheng, Yu-Qing Duan, Kai-Li Ji, Run-Ling Wang*, Bing-He Wang*. Tuning the reaction rates of fluoride probes for detection in aqueous solution[J]. RSC Advances, 2016, 6, 25242–25245
3. Xiao-Bo Li, Lei Dong, Wei-RenXu, Soumitra S. Bhuyan, Chenglung Chen, Run-Ling Wang. Study of SHP-2 (PTPN11) allosterism on structural movement using solution perturbed molecular dynamics simulation[J]. Journal of Molecular Liquids, 2016, 223, 509-515
4. Liu-Qing Wen, Lan-Lan Zang, Kenneth Huang, Shan-Shan Li, Run-Ling Wang*, Peng George Wang*. Efficient enzymatic synthesis of L-rhamnulose and L-fuculose[J]. Bioorganic & Medicinal Chemistry Letters, 2016, 26 (3): 969-972
5. Jun Zhang, Xin Liu, Shu-Qing Wang, Gui-You Liu, Wei-RenXu, Xian-Chao Cheng *, Run-Ling Wang*. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator activated receptor-γ by core hopping of telmisartan[J]. Journal of Biomolecular Structure and Dynamics, 2016, 7, 1-16
6. Mei-Yan Wang, Yuan-Yuan Jin, Hui-Yu Wei, Li-Song Zhang, Su-Xia Sun, Xiu-Bo Chen, Wei-Li Dong, Wei-Ren Xu, Xian-Chao Cheng*, Run-Ling Wang*. Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors[J]. European Journal of Medicinal Chemistry, 2015, 103, 91-104
7. Xue-Jiao Wang, Jun Zhang, Shu-Qing Wang, Wei-Ren Xu, Xian-Chao Cheng, Run-Ling Wang*.Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone[J]. Drug Design, Development and Therapy, 2014, 8, 2255-2262
8. Ying Ma, Yuan-Yuan Jin, Ye-Liu Wang, Run-Ling Wang*, Xin-Hua Lu, De-Xin Kong, Wei-Ren Xu. The Discovery of a Novel and Selective Inhibitor of PTP1B Over TCPTP: 3D-QSAR Pharmacophore Modeling, Virtual Screening, Synthesis, and Biological Evaluation[J]. Chemical Biology & Drug Design, 2014, 83, 697-709
9. Lan-LanZang, Xue-Jiao Wang, Xiao-Bo Li, Shu-Qing Wang, Wei-RenXu, Xian-Bin Xie, Xian-Chao Cheng, Huan Ma, Run-Ling Wang*. SAHA-based novel HDAC inhibitor design by core hopping method[J]. Journal of Molecular Graphics and Modelling, 2014, 54, 10-18
10. Jing-Wei Wu, Huan Zhang, Yu-Qing Duan, Wei-Li Dong, Xian-Chao Cheng, Shu-Qing Wang, Run-Ling Wang*. Design Novel Inhibitors for Treating Cancer by Targeting Cdc25B Catalytic Domain with De Novo Design[J]. Combinatorial chemistry & high throughput screening, 2014, 17(10): 837-847
11. Yu-Qing Duan, Ying Ma, Xue-Jiao Wang, Yuan-Yuan Jin, Run-Ling Wang*, Wei-Li Dong, Wei-Ren Xu, De-Xin Kong, Shu-Qing Wang*.Design Potential Selective Inhibitors for Treating Cancer by Targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with Core Hopping Approach [J]. Protein & Peptide Letters, 2014, 21(6): 556-563
12. Yuan-Yuan Jin, Ying Ma, Quan-Xiong Gao, Run-Ling Wang*, Shu-Qing Wang, Wei-Ren Xu. Design of specific inhibitors of the protein tyrosine phosphatase SHP-2 by virtual screening and core hopping method[J]. Molecular Simulation, 2014, 40(12): 904–911
13. Wei-Bing Zhang, Wen-Bo Liu, Jing-Wei Wu, Wei-Li Dong, Shu-Qing Wang*, Run-Ling Wang*. The derivatives of oseltamivir design passing through the important cleft of neuraminidase against influenza virus by de novo design [J].Molecular Simulation, 2014, 40(15): 1209–1217
14. Ying Ma, Su-Xia Sun, Xian-Chao Cheng, Shu-Qing Wang, Wei-Li Dong, Run-Ling Wang*, Wei-Ren Xu. Design and Synthesis of Imidazolidine-2,4-Dione Derivatives as Selective Inhibitors by Targeting Protein Tyrosine Phosphatase-1B Over T-Cell Protein Tyrosine Phosphatase [J]. Chemical Biology & Drug Design, 2013, 82(5): 595-602
15. Su-Xia Sun, Xiao-Bo Li, Wen-Bo Liu, Ying Ma, Run-Ling Wang*, Xian-Chao Cheng, Shu-Qing Wang, Wei Liu. Design, Synthesis, Biological Activity and Molecular Dynamics Studies of Specific Protein Tyrosine Phosphatase 1B Inhibitors over SHP-2[J]. International journal of molecular sciences, 2013, 14, 12661-12674
16. Lei Liu, Ying Ma, Run-Ling Wang*, Wei-Ren Xu, Shu-Qing Wang*, Kuo-Chen Chou. Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics[J]. Drug Design Development and Therapy, 2013, 7, 279-288
17.Wen-Ming Li, Xiao-Bo Li, Su-Xia Sun, Jing Liang, Run-Ling Wang*, Shu-Qing Wang. Agonist and antagonist recognition studies for oestrogen receptor by molecular dynamics Simulation[J]. Molecular Simulation, 2013, 39(3):228-233
18. Xian-Chao Cheng, Run-Ling Wang*, Zhen-Ke Dong, Jing Li, Yao-Yuan Li, Rong-Rong Li. Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold[J]. Bioorganic & Medicinal Chemistry, 2012, 20, 5738–5744
19. Ying Ma, Shu-Qing Wang*, Wei-Ren Xu, Run-Ling Wang*, Kuo-Chen Chou. Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach[J].PLoS ONE, 2012, 7(6): e38546
20.Synthesis, biological evaluation and 3D-QSAR studies of 1,2,4-triazole-5-substituted carboxylic acid bioisosteres as uric acid transporter 1 (URAT1)inhibitors for the treatment of hyperuricemia associated with gout,Jing-wei Wu, Ling Yinb, Yu-qiang Liu, Huan Zhang, Ya-fei Xie, Run-ling Wang, Gui-long Zhao，Bioorganic & Medicinal Chemistry Letters, 2019,29,383-388
21.Rui-Rui Wang, Ying Ma, Shan Du, Wei-Ya Li, Ying-Zhan Sun, Hui Zhou, Run-Ling Wang，Exploring the reason for increased activity of SHP2 caused by D61Y,mutation through molecular dynamics，Computational Biology and Chemistry，2019,78,133-1493
22.Wen-Yan Jin, Ying Ma, Wei-Ya Li, Hong-Lian Li, Run-Ling Wang*,Scaffold-based novel SHP2 allosteric inhibitors design using,Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics, Computational Biology and Chemistry 2018,73 :179–188
23.Wei‐Ya Li，Hui‐Yu Wei，Ying‐Zhan Sun，Hui Zhou，Ying Ma, Run‐Ling Wang，Exploring the effect of E76K mutation on SHP2 cause, gain‐of‐function activity by a molecular dynamics study，J Cell Biochem. 2018，1-16.
24.Hong-Lian Li, Ying Ma, Ying Ma, Yu Li, Xiu-Bo Chen, Wei-Li Dong*, Run-Ling Wang*,The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches , Oncotarget, 2017, 8 ( 20): 33225-33240


科研项目

1.国家自然科学基金面上项目（**）：与幼年型粒单细胞性白血病相关的SHP2突变体E76K、D61G选择性抑制剂的设计、合成及其活性研究，2018.01- 2021.12；
2.国家自然科学基金国际（地区）合作与交流项目（）：以SHP2 为靶点的抗白血病药物的设计、合成及活性筛选，2016.1.1-2018.12.31；
3.国家自然科学基金面上项目（**）：高选择性蛋白酪氨酸磷酸酶SHP2抑制剂的研究、2013.01-2016.12；
4.国家自然科学基金面上项目（**）：具有PTP-1B、PPAR-α、PPAR-γ三重作用的抗糖尿病先导物的设计、合成及活性研究、2010.01-2012.12；
5.天津市自然科学基金重点项目：09JCZDJC21600、基于PTP1B酶结构的新型降糖药先导物的研究、2009.4-2012.3；
6.高等学校博士学科点专项科研基金（010）：具有三靶标（PTP-1B、PPAR-α/γ）作用的抗糖尿病先导物的设计、合成及活性研究，2010.01-2012.12。
7.选择性SHP2突变体D61G、E76K抑制剂研究，天津市自然科学基金重点项目，（16JCZDJC32500），2016.4-2019.3

荣誉奖励

2016年获得第九届天津市高等学校教学名师奖；
2009年被评为天津市优秀教师；
2009年主持完成的《药学专业实践教学的改革与实践》获高等教育天津市级教学成果二等奖；2008年获天津医科大学教学成果一等奖；
2013获得“第十二届‘挑战杯’天津市大学生课外学术科技作品竞赛优秀指导教师奖；
2003年主持研发的《精氨酸布洛芬及其糖浆剂》获天津市科技进步三等奖；
1997年主持的《布洛芬糖浆剂生物利用度研究》项目获天津市卫生局科技进步三等奖；
2003年度获天津市“十五”立功先进个人荣誉称号；
2001年主持的化学实验Ⅱ改革获天津市教委实验室建设单项奖。
2006年获天津医科大学“十五”科技工作先进个人；
2012年获得“天津医科大学科技创新优秀指导教师”荣誉称号；
2002年“九五”期间在科学研究过程中，获得天津医科大学突出贡献奖；
2001年、1999年被评为天津医科大学优秀教师；
1997年获天津市卫生局优秀青年技术人员称号；
1998-2000年获天津医科大学跨世纪人才资助；